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1. Introduction
1.1. What is it a gene polymorphism?
Every protein is coded by a gene and every human gene exists in several allelic variants,
which occur due to mutations and are inherited together with other genetic characteristics
from parents to children. If a certain allelic variant occurs within the population with at least
a 1% frequency, it is known as a common gene polymorphism. However, if the frequency in
the given population is below 1%, it is referred to as a rare allelic variant.
An allele having a majority within a population is called a wild type or standard. Allele(s),
which are a minority within a population, are known as a variant, non-standard or some‐
times a mutant allele.
Percentage frequencies of individual alleles for the same gene polymorphisms in various
populations  are  often significantly  different,  which makes  many clinical  studies  compli‐
cated. For example, variant allele asterisk *10 of gene coding for cytochrome CYP2D6 co‐
des an unstable enzyme with decreasing activity.  It  can result in the slower metabolism
of some drugs, e.g. antidepressants. The frequency of this variant allele is from 1 - 2% in
the Caucasian population but  51% in the Asian population.  The gene CYP2D6 can also
be duplicated or multiplicated. The amount of enzyme is from 2 to 13 times higher com‐
pared to the standard gene allele, which leads to ultra rapid metabolism. The occurrence
of this polymorphism differs.  For example,  in Central Europe, the occurrence is 4% and
in Saudi Arabia it is 29%.
© 2012 Ladislava et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.2. Molecular biological basis of gene polymorphism
The molecular biological basis of gene polymorphism is a mutation of the given gene, in
which individual variant alleles occur. Mutations can have a form of replacement or substi‐
tution when one or more nucleotides in a gene are replaced by another one; or they can have
a form of frameshift mutations, including deletions or insertions, when one or more nucleo‐
tides in a gene are missing (=deletion) or are redundant (=insertion). Frameshift mutations
lead to frameshift changes, and from the position of the mutation other amino acids can be
incorporated in the protein chain or a stop codon is generated, which prematurely termi‐
nates transcription of the protein chain.
The most common mutation in gene polymorphisms is the replacement of a single nucleo‐
tide, or the so-called single nucleotide polymorphism or SNP.
SNP represents 90% of all gene polymorphisms in humans. There is a freely accessible data‐
base (http://www.ncbi.nlm.nih.gov/SNP/index.html), which lists over 38 million identified
and validated SNPs, and their number grows every day. SNPs are also associated into
blocks - haplotypes, which are usually inherited together. Therefore, the identification of a
single SNP can theoretically identify the whole haplotype.
1.3. Methods of gene polymorphisms detection
Presently, the basic method of molecular diagnostics is a polymerase chain reaction, PCR. A
basic PCR reaction contains two primers and serves for the detection of one specific locus in
the form of amplicon of a pre-calculated size.
For the purposes of finding simple nucleotide polymorphisms, the products of amplification
can be further digested by restriction endonuclease, and this arrangement is marked PCR-
REA (PCR-restriction enzyme analysis), PRA (primer restriction analysis) or PCR-RFLP
(PCR-restriction fragment length polymorphism) [1]. This method allows for the analysis of
any gene up to a length of approximately 5 kbp. Amplicons of the same length are the result
of PCR amplification. These amplicons are further digested by a suitable restriction endonu‐
clease and the resulting products analyzed by gel electrophoresis. It is a very simple, fast
and highly sensitive detection method for single gene polymorphisms. However, it can only
be used for determining gene polymorphism when two alleles in the given locus differ in
such a way that one contains a restriction locus for the given endonuclease and the other
does not.
DNA sequencing is the determination of the primary structure of nucleotide chain, i.e. the
sequence of nucleotides in DNA molecules. It is a final and definite determination of the ba‐
sic information which DNA carries. Knowledge of the DNA sequence allows to find the
reading frames of potential genes, to analyse exons and introns in structural genes, and to
determine the sequences of amino acid-coded proteins, and is usable for the detection of
regulatory genes and regulatory areas, repetitive sequences and all simple nucleotide poly‐
morphisms. There are two fundamentally different methods which are commonly used for
sequencing. The first method is based on terminating DNA chains using chemical substan‐
ces and is called Maxam-Gilbert Sequencing [2]. The second method uses the inhibition of
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the enzymatic synthesis of DNA by dideoxyterminators, and is known as Sanger’s Sequenc‐
ing Method [3]. Both methods use the same original material, i.e. DNA fragments obtained,
for example, by restriction or cloned in vector. They can also be products of polymerase
chain reaction. The most recent development in sequencing methods has been the introduc‐
tion of devices for automatic sequencing. This method uses enzymatic Sanger’s method and
allows for the determination and processing of DNA sequences at a much faster rate as well
as being more economical than standard techniques [4].
1.4. Clinical consequences of gene polymorphism
The clinical consequences of mutations on the function and the amount of coding protein
(phenotype) depend on their localization and can influence the development of certain dis‐
eases or a patient’s response to a particular drug regarding their effectiveness, as well as the
safety of a chosen pharmacotherapy.
A mutation can be located in the coding areas of a gene (exons), in the regulatory areas (pro‐
moter or generally in the 5´ region of gene) or at the exon–intron interface, i.e. in the exon-
intron primary transcript splicing site.
Mutation in the exon area (the coding part of a gene), is manifested by the substitution of
amino acids or from a change of the amino acid sequence in the protein chain.
If a gene codes for an enzyme, the result of the mutation is a change in the pharmacokinetic
parameters at the drug metabolization level, i.e. leading to the altered activity of this en‐
zyme, or to its complete inactivation and consequent acceleration or deceleration of the met‐
abolic processes leading to the degradation of the active substance in the drug or, on the
other hand, to the formation of the active substance in case of the “prodrug”. If a gene codes
for a receptor protein, the mutation can lead to a change of the receptor’s ability to bind a
ligand and to activate the signaling cascade. This can cause changes in the pharmacodynam‐
ic parameters of the drug. Membrane carriers, protein and P-glycoprotein transporters cod‐
ed by a variant allele of a gene can have an altered affinity to its substrates; variant channel
proteins can create channels with different electrical and chemical characteristics, and this
can result in a change of ionic homeostasis.
Mutation in the regulatory areas of a gene leads to changes in gene expression, i.e. to either
upregulation or downregulation. It is manifested by the lack or excess of protein coded by
this gene. If the mutation is located in the interface area between intron and exon in the pri‐
mary transcript splicing site, this can result in the faulty splicing of the primary transcript,
and can cause a shortening or lengthening of a protein chain, which leads to the loss or re‐
striction of functions of the coding protein.The splicing site is distinguishable by specific ri‐
bonucleoproteins. If the nucleotide sequences in this area differ from the standard gene as a
result of mutation, incorrect splicing of primary transcript hnRNA to mRNA occurs.
The presence of variant alleles can have an impact not only on metabolic processes (absorp‐
tion, distribution and drug elimination), it can also influence the effectiveness and safety of
the chosen pharmacotherapy. Furthermore, it represents an increased risk of the develop‐
ment of certain diseases due to the changing structures or functions of several regulatory
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proteins, which influence the physiological processes of the body. Disease development is
caused by both genetic and environmental factors. Additionally, a patient’s sensitivity to ex‐
ternal factors is varied and this variability is again, genetically conditioned.
2. The role of candidate genes in etiopathogenesis of inflammatory
bowel diseases
Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the gastrointestinal
tract. The term covers two specific conditions – Crohn’s disease (CD) and ulcerative colitis
(UC), which differ in their anatomic location, intensity and the scope of their affect on the
intestinal mucosa. The etiopathogenesis of these two conditions is not fully understood to
date. However, several studies have confirmed that there are external factors, together with
genetic predisposition, which contribute to the diseases’ onset [5]. The significant role of ge‐
netic predisposition is supported by a relatively high familial occurrence of Crohn’s disease,
a high concordance in monozygotic twins up to 67% a connection with patients’ ethnic or
racial character, and parallel incidences of other rare genetic syndromes. The risk of Crohn’s
disease is 3–5 times higher in the first degree relatives, and a familial occurrence was found
in 15–20% of cases. However, genetic predisposition is more important in CD than in UC [6–
8]. Genes whose products somehow influence the development of the inflammatory reaction
are called “candidate genes,” and they are located at different places on the genome marked
from IBD1 to IBD9 [9]. These candidate genomic loci include NOD2/CARD15, ICAM-1,
CCR5, MDR1, TLR4 and other genes [10–12]. At present, the correlation between the genetic
makeup of an individual and the predisposition to contract a disease has been studied as
well as its connection with the clinical characteristic of a disease.
2.1. NOD2/CARD15 gene
NOD2 (nucleotide-binding oligomerization domain) is a protein expressed by several im‐
mune system cells (monocytes, macrophages and dendritic cells). It is a key molecule that
reacts to the intracellular presence of peptidoglycans of bacterial origin [13]. The binding of
peptidoglycans initiates the signalling cascade, ending with NF-κB activation and the ex‐
pression of pro-inflammatory genes including TNFα [14,15]. In the gene for the protein
NOD2, several polymorphisms were described. Substitutions at positions 702Arg>Trp,
908Gly>Arg and the frameshift mutation (cytosine nucleotide insertion) at position 1007
(3020fsinsC) are most often linked with the disruption of receptor functions. These three
mutations represent 81% mutations of NOD2 in CD patients [16]. The presence of the latter
mutation leads to the disruption of the reading frame during the transcription and to the ter‐
mination of proteosynthesis due to a newly formed stop codon [17]. For the polymorphisms
at positions 702 and 908 was described a comparable or just a slightly increased NF-κB in‐
duction [18]. Furthermore, the presence of the frameshift mutation at position 1007 limits the
structure and function of the NOD2 protein to such an extent that the NF-κB activation in
the presence of peptidoglycan is (MDP used as a standard inductor) undetectable [15] and
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TNFα expression is decreased [19–21]. The described polymorphisms have a relatively high
frequency in the Caucasian population. Carriers of one mutant allele have a 2 to 4 times
higher risk of CD outbreak and recessive homozygotes at 20–40 times higher [20]. An associ‐
ation between the occurrence of the 1007fs frameshift mutation in the NOD2 gene and the
IBD incidence has also been confirmed. A similar association, somewhat less significant, was
also discovered in the 908Gly>Arg polymorphism [21]. Patients with mutations in the gene
CARD15/NOD2 also showed a decreased expression of defensines [22]. Mutations can there‐
fore be predisposed to CD not only directly, but indirectly as well, i.e. by obstructing the
natural antimicrobial immunity mediated by defensines.
2.2. ICAM-1 gene
Lately, the association between IBD and the ICAM-1 gene has also been intensively studied.
This gene codes for the intracellular adhesive molecule ICAM-1 which performs many phys‐
iological functions. It controls the migration of inflammatory elements, participates in the
presentation of antigen, and because it is expressed by various cell types, it is involved in
many signalling cascades [23]. Its significantly increased expression in the intestinal mucosa
was observed in inflammatory bowel diseases. In the ICAM-1 gene, at least 20 SNPs were
identified. A SNP marked 469Lys>Glu has also been linked with IBD [24]. A substitution of
nucleotides leads to the substitution of amino acid in the 5th immunoglobulin domain of
ICAM-1, which is important for the adhesion of B cells and dendritic cells [25]. An altered
function of the protein ICAM-1 potentially contributes to the genetic predisposition for in‐
flammatory diseases and immunity disorders. The prevalence of the 469Lys>Glu polymor‐
phism has also been linked with multiple sclerosis [26], Behcet’s disease [27], psoriatic and
rheumatic arthritis [28] and other chronic inflammatory diseases [29].
2.3. CCR5 gene
Another gene, which intervenes in the reactions of the immune system, is the gene that co‐
des for the receptor CCR5, whose ligands are CC chemokines. The endogenous functions of
this receptor include the mobilization of the relevant immune system cells and the targeting
of their chemotaxis into the inflamed area. The CCR5 receptor is responsible for the trans‐
port of chemokine CC and participates in the entering of virus particles of the human immu‐
nodeficiency virus (HIV-1) into macrophages [30].
Its regulatory role lies in the preference of the Th1 immune response and suppression of the
Th2 immune pathway. It participates, for example, in the immune defence against Mycobac‐
terium tuberculosis, [31]. In the 1990s, it was discovered that the gene for this receptor occurs
in various allelic forms in the population. In particular, a 32 base pairs deletion in the gene
CCR5 was studied because it leads to the expression of a shorter, and therefore non-func‐
tional receptor in the cell membrane and consequently to the disrupted communication be‐
tween cells of the immune system. This deletion mutation is associated with the onset of
pathological inflammatory conditions, such as sarcoidosis [32], rheumatoid arthritis [33] and
periodontitis [34]. A cellular immunity disorder caused by the non-functional receptor
CCR5 could play some role in IBD development.
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2.4. TLR4 gene
The Toll receptor was originally described in Drosophila, where its function lies in the im‐
mune defence against fungal and yeast infections in adults. It was found that the intracellu‐
lar part of this receptor molecule often resembles parts similar to a completely different
receptor – for cytokine interleukin-1 (IL-1). In humans, a total of 10 receptors have been de‐
scribed in which their amino acid sequence is similar to the original Toll receptor of Droso‐
phila [35]. Thus, they were named Toll-like receptors. Individual TLR receptors differ in
their presence in various cell populations and in their affinity for various ligands. TLR4 in
particular is a model ligand of lipopolysaccharide (LPS), which activates the NF-κB expres‐
sion after binding to the extracellular domain of a receptor, and, in the next step, the expres‐
sion of pro-inflammatory cytokines (TNFα, IL). The gene for TLR4 is located on
chromosome 9, in the area 9q32-33, and is expressed by monocytes, macrophages, masto‐
cytes and immature dendritic cells, as well as by intestinal cells in a small amount in the api‐
cal part of epithelium, and also by renal, corneal and pulmonary epithelial cells [36]. A
substitution of adenine for guanine at position 896 (896A>G) was detected by direct se‐
quencing. This substitution is manifested on the amino acid sequence level by the substitu‐
tion of a conservative aspargic acid with glycine at position 299 (299Asp>Gly). This single
nucleotide polymorphism (SNP) is located in exon 4 of the gene for TLR4 and results in pro‐
duction of an altered extracellular domain of this receptor.
Another SNP was found at position 399 of the amino acid sequence, where non-conservative
threonine was replaced by isoleucine (399Thr>Ile). This mutation cosegregates with muta‐
tion 299Asp>Gly [37]. Polymorphisms in the gene for TLR4 are linked with various diseases
such as chronic periodontitis [38], COPD [39], Behcet’s disease [40], septic shock [41] or IBD
[42] and are associated with the disruption of intracellular processes leading to NF-κB in‐
duction and TNFα expression.
2.5. TNFα gene
Several SNPs have been described in the TNFα gene sequence; in the promoter, intron, as well as
exon areas. In the promoter area, the following polymorphisms have been described: substitu‐
tions at nucleotide positions –1031T>C, –863 C>A, –857 C>A, –851C>T, –419 G>C, –376 G>A, –
308 G>A, –238 G>A, –163 G>A, and –49 G>A. In the intron 1 sequence, there is the substitution of
488G>A [43]. The mutation in the gene TNFα results in a changed level of the gene expression
and therefore a different amount of active cytokine. As was mentioned before, the physiological
or pathological manifestations of its effect are based on TNFα quantity. In this context, the poly‐
morphisms in the promoter area of the gene, which interacts with the transcription factors, are
highlighted. Nucleotide polymorphisms at positions –376, –308 and –238 are most often men‐
tioned in connection with the change of the gene expression level.
2.5.1. Polymorphism –376G>A
Transcription factor OCT-1 binds at position –376. It was proved that the transcription factor
binds with a higher preference to the variant allele –376A [44].
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2.5.2. Polymorphism –308G>A
This polymorphism is most often mentioned in connection with increased TNFα produc‐
tion. At the same time, it is the most closely studied predisposition factor for chronic inflam‐
matory diseases including IBD. Braun et al. [45] as well as Sashio et al. [46] confirmed in
vitro a higher transcription activity of the variant allele –308A. In his study of the Czech pop‐
ulation, Sykora et al. [47] stated that a statistically significant association existed between the
–308G>A polymorphism and the occurrence of UC in child patients. He also discovered that
patients who were carriers of at least one variant allele, i.e. carriers of the genotype G/A or
A/A, had significantly higher levels of C-reactive protein (CRP) compared with carriers of
the standard G/G genotype [47]. A study of the Mexican population confirmed that there
was a significantly higher frequency of the variant allele –308A in the gene for TNFα in pa‐
tients with UC, compared with a healthy population [48,49] found a significantly higher risk
of pancolitis in carriers of the variant allele –308A. The risk is 1.91 times higher in compari‐
son with carriers of the standard genotype [49]. A meta-analysis of 27 studies confirmed a
significantly higher risk of the onset of ulcerative colitis and Crohn’s disease in carriers of
the non-standard A/A genotype polymorphism –308G>A in the European population [50].
2.5.3. Polymorphism –238G>A
Some authors stated that the variant allele –238A is associated with a high expression of
TNFα, but other groups of scientists have not confirmed this statement [51,52]. It is also as‐
sumed that the levels of the TNFα transcription are influenced by DNA sections situated
outside the promoter area.
3. Gene polymorphisms associated with inflammatory bowel diseases:
Differences between CD and UC patients
At present, it is generally considered that IBDs have a genetic background and that there are
environmental factors which can trigger the disease [53].
The locus IBD1 is the most often linked with a genetic predisposition to IBD. It is situated,
along with others, in the gene NOD2/CARD15. In our study, we studied three polymor‐
phisms in this gene (702Arg>Trp, 908Gly>Arg and 1007fs insC) in 101 patients with CD, 35
patients with UC and 78 healthy volunteers. At least one variant allele was found in 56.3%
of the patients with CD, whereas in patients with UC it was found in only 14.6%, and in
healthy volunteers, 20%. Recessive homozygotes (carriers of two non-standard alleles in the
gene NOD2/CARD15) were found only in the group of patients with CD. The most serious
clinical impact and therefore the strongest association with CD, was confirmed in the frame‐
shift mutation (Leu1007fs insC) in this gene – see Table 1. Similar results were reported by
other authors [5, 54 - 56] and also by our research team in their previous works [21,8]
The second monitored mutation in this gene (702Arg>Trp) was significantly less frequent in
patients with UC compared with patients with CD. In the third mutation of the gene, substi‐
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tution 908Gly>Arg, we did not find any statistical association with CD or UC. The frequency
of this allele in Czech and Slovak populations is very low; the allele frequency in the group
of healthy volunteers was 2%. Brant et al. [54], unlike our results, found a significant connec‐
tion between Crohn’s disease and the mutation Gly908Arg in a larger set of patients.
Gene Variant allele Patients with CD Patients with UC Health volunteers
NOD2/CARD15
702Trp 9.90• 2.86• 8.97
908Arg 3.96 1.43 1.92
Leu1007fs 16.83* 8.57 5.77*
ICAM-1 469Glu 48.02** 37.14Δ 26.28**, Δ
CCR5 Δ32 8.91• 17.14• 14.74
Table 1. Frequency (in %) of variant allele of all tested genes and statistically significant differences among groups.
Statistical analysis by Fisher test *P<0.01; **P<0.05 - statistical significant differences between group of CD patients and
group of healt volunteers ΔP<0.01; ΔΔP<0.05 - statistical significant differences between group of UC patients and
group of healt volunteers •P<0.01; ••P<0.05 - statistical significant differences between group of CD patients and UC
patients.
All present studies imply that the genetic predisposition to IBD is polygenic, i.e. the process
of pathogenesis includes more genes, and the presence of individual mutations is cumula‐
tive, which means that the occurrence of a larger number of mutations in the same gene in‐
creases the probability of a phenotype change, or, i.e., the loss of function of a protein coded
by this particular gene. We found a highly significant difference between the group of pa‐
tients with Crohn’s disease and the control group (P = 0.0019) in the total number of moni‐
tored mutations. Our results also confirmed that the average number of mutations in the
gene NOD2/CARD15 calculated in one person is significantly (P < 0.05) higher in the group
of patients with CD, when compared with UC or the control group. Furthermore, patients
with UC revealed a lower frequency of these mutations than the control group, but the re‐
sult was not significant. It seems that the occurrence of variant alleles in the gene NOD2/
CARD15 is really typical for patients with Crohn’s disease [5].
The ICAM-1 gene plays a key role in the migration of neutrophils to the inflammation area
and is connected with several inflammatory diseases. Matsuzawa [29] reported a significant‐
ly increased frequency of the variant allele for the polymorphism 469Lys>Glu in this gene
among Japanese patients with CD. We also confirmed a strong association between the oc‐
currence of a non-standard allele for this polymorphism and CD (P = 0.0002) in our set (pa‐
tients of Caucasian population). Carriers of two non-standard alleles in this gene were up to
83% in patients with Crohn’s disease, but only 0.6% in patients with UC and less than one
percent in healthy individuals. The odds ratio implies that the risk of CD in these recessive
homozygotes is 10.6 times (95% CI = 2.9–38.7) higher than in people with standard alleles in
the gene ICAM-1, and the risk of UC is 3.1times (95% CI = 0.55–17.35) higher.
Herfarth et al. [57] suggested that the mutation in chemokine receptors CCR5 could play a
key role in the regulation of the intestinal immune response in CD. They did not succeed in
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finding a higher frequency of the deletion allele Δ32 in patients with CD, but they found out
that the polymorphism in the gene for the CCR5 receptor can contribute to the disease pro‐
gression and its location. The results of our study suggest that patients with CD have a dele‐
tion allele Δ32 in the gene CCR5 significantly less often compared with patients having UC.
The deletion allele is found in patients with UC insignificantly more often compared with
healthy volunteers.
Polymorphism –308G>A in the gene for TNFα is most often mentioned in connection with
the increased production of this cytokine, therefore it is studied as a predisposition factor for
chronic inflammatory diseases, including IBD. The highest frequency of the non-standard al‐
lele of this polymorphism (25%) was found in the group of patients with indeterminated col‐
itis. In the groups of patients diagnosed with CD and UC, the allele frequency was almost
identical – 13.96% and 14.29%. To compare the occurrence of the variant allele in the evalu‐
ated group of patients, a control group of healthy individuals was used. The overall fre‐
quency of the variant allele for the polymorphism –308G>A in the control group of healthy
individuals reached 8.46%. When comparing the allele frequencies in both groups, i.e.
healthy volunteers to the group of patients with IBD, it is obvious that the variant allele of
the monitored polymorphism occurs 1.86 times more frequently in the group of patients
compared with the group of healthy individuals, and this probability is highly significant (P
= 0.0002). In the group of patients with indeterminate colitis, the variant allele occurs 3.95
times more often compared with the group of healthy volunteers.
The allelic frequency of the monitored polymorphism in the entire Caucasian population is
generally about 11% [58]. The results indicate a possible role of the variant allele of the poly‐
morphism –308G>A in the gene TNFα as a predisposing factor for the onset of IBD. An in‐
creased level of TNFα can lead to a predisposition to a more intense inflammatory reaction
and represents one of the risk factors contributing to the development of this disease [49,50].
From the available data it is obvious that genetic factors can determine the IBD character,
especially in case of CD. In monozygous twins with CD, 7 out of 9 cases showed a corre‐
spondence to the disease location, and in 6 out of 9 cases the disease was diagnosed within 2
years. However, the disease behaviour did not reveal any correspondence [60]. Available
data imply that the mutation in the gene CARD15/NOD2 can be connected with the affected
ileum, or preferential occurrence of inflammation in the ileocaecal area [6] and with the sten‐
otic form of the disease [59,60]. There has also been a discussion regarding the impact of mu‐
tation in this gene on the onset age of Crohn’s disease [61]. Herfarth [57] reported that
carriers of the deletion mutation Δ32 in the gene CCR5 are less often affected in the upper
part of gastro intestinal tract (GIT), but they are more susceptible to the development of
strictures. Due to the absence of CCR5 receptors and decreased ability of a cell to initiate an
inflammatory response [57], carriers of the deletion mutation Δ32 experience less often the
aggressive progress of the disease (perforating or fistula type of CD) [57].
However, our results revealed that the perforating type of CD occurs significantly more of‐
ten in patients with the deletion allele Δ32, compared with patients with the non-stenotic
form of the disease, in whom the occurrence of this deletion allele was significantly lower.
Therefore we did not confirm the results of Herfarth et al. [57].
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Statistical analyses of our results confirmed an association between the polymorphism in the
gene ICAM-1 and CD outbreak. The occurrence of the variant allele 469Glu in the gene
ICAM-1, both in heterozygous and homozygous state, is statistically significantly higher in
patiens, in whom CD broke out before 16 years of age, compared with patients, in whom the
disease broke out between 16 and 40 years of age [8] – see Figure 1. However, we did not
confirm the results of Hradský et al. [56] that the frameshift mutation 1007fs in the gene
NOD2/CARD15 occurs more often in child patients with CD than in adult patients. This was
probably caused by the fact that the group of patients with a very early clinical manifesta‐
tion of the disease consisted of only 10 individuals. Nevertheless, even our results imply
that the greater the genetic predisposition is, the earlier the age of manifestation and disease
diagnosis. For example, three or more mutations in all of the monitored candidate genes
were detected in 46.2% of young patients, in whom the clinical manifestations of the disease
appeared before 16 years of age, but only in 26.3% of patients did the disease manifested
from 16 to 40 years of age and in 0% of patients with CD after 40 years of age [8].
Figure 1. Influence of ICAM-1 gene mutation on the age of CD manifestation. Note: +/+: standard homozygote (carri‐
er of two wild type alleles); +/- : heterozygote (carrier of one variant allele); -/- : variant homozygote (carrier of two
variant alleles).
4. Pharmacotherapy of inflammatory bowel diseases and genes affecting
drug metabolism, the occurrence of adverse effects and response to
therapy
At the present time, there is no curative therapy and hence the pharmacological treatment
focuses on inflammation control, eliminating disease symptoms and improving of the quali‐
ty of life. IBD pharmacology utilises a wide scale of drugs including salicylates, glucocorti‐
coids, and immunosuppressives (e.g. thioguanine derivatives, methotrexate and
cyclosporine).
In clinical practice, IBD therapy, using a step-by step system, is influenced by the intensity
of the disease and the effectiveness of previous therapy.
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At present, aminosalicylates constitute the substantial part of the conservative treatment of
IBD. When this therapy is insufficient, corticoid or immunosuppressive therapy is applied,
either separately or combined. The highest level is biological therapy. Many authors indicate
that TNFα as a pro-inflammatory cytokine plays a crucial role in the pathogenesis of many
diseases, including IBD. The use of monoclonal antibodies, which neutralize TNFα, seems to
be a very effective method of treatment. IBD requires long-term treatment. It is also necessa‐
ry to mention surgical resection of the affected part of the intestine, which is used as an al‐
ternative method or pharmacotherapy supplement.
Patients are potentially exposed to the side effects of many drugs. Some toxic effects could
be caused by overdose induced by a low metabolism and the elimination of effective sub‐
stances. However, mechanisms of metabolism and elimination are complex; there are some
crucial enzymatic proteins whose activity affects metabolism on an important therapeutical
level. Single nucleotide polymorphisms (SNPs) of these genes affect enzyme structure and
activity and are therefore, therapeutically significant.
4.1. Aminosalicylates
Aminosalicylates has been used in IBD therapy since the 1940s. Historically, the first prepa‐
ration in this drug group was Sulfasalazine. It is a prodrug, which is dissociated in the intes‐
tine by bacteria into the active substance 5-ASA and pharmacologically inactive
sulfapyridine.
During this therapy, adverse effects develop in 5 to 50% of individuals (most common are
nausea, vomiting, general asthenia, headache, abdominal discomfort and rarely haemolytic
anaemia and rash), in which some patients require termination of the therapy. The cause of
these undesired effects is considered to be the sulfonamide component of the substance. Sul‐
fapyridine released in the intestine is absorbed into the systemic circulation and acetylated
in the liver by N-acetyltransferase (NAT) into N-acetylsulfapyridine. N-acetyltransferase is a
cytosol enzyme with broad distribution into various tissues. The highest activity was ob‐
served in liver cells, intestinal epithelium and the urinary bladder. In contrast, an insignifi‐
cant activity of this enzyme was found in plasma, brain and muscle [62]. N-acetyltransferase
exists in two different and independently regulated isoforms: NAT1 and NAT2, which differ
in their affinity to various substrates. The NAT2 isoenzyme in the liver is a lot more impor‐
tant for sulfapyridine acetylation than NAT1 present in the liver and gut.
4.1.1. Polymorphisms influencing aminosalicylates therapy
The genes for NAT1 and NAT2 are located on chromosome 8p22. The NAT2 gene is poly‐
morphous and to date, several allelic variants have been identified with various impacts on
the acetylation activity of these enzymes. Any population can be divided into fast, inter‐
mediate and slow acetylators, where over 50% of the Caucasian population represent the
slow acetylator phenotype. Slow acetylators, unlike the fast ones, have higher concentra‐
tions of plasma sulfapyridine and its elimination half-time is longer. Sulfapyridine is re‐
sponsible for various adverse effects; therefore, the NAT2 acetylation phenotype/genotype
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could be important for the prediction of toxicity. Several studies confirmed higher inciden‐
ces of adverse effects in slow acetylators [63–65]. Nevertheless, acetylation status is not the
only factor regulating plasma concentration. Sulfapyridine is not only acetylated, it is also
metabolised by the hydroxylation of an unknown polymorphous enzyme [66,67] and the
high hydroxylation capacity can, in some individuals, compensate for the low level of acety‐
lation. Due to the frequent occurrence of adverse effects, Sulfasalazine has been replaced by
the active component alone, i.e. 5-aminosalicylic acid (5-ASA). 5-ASA is acetylated by poly‐
morphous NAT1 into the pharmacologically inactive metabolite, therefore, there is a hy‐
pothesis that the increased acetylation capacity of NAT1 could be causing the decreased
effectiveness of 5-ASA. Studies in patients with ulcerous colitis did not confirm the correla‐
tion between the NAT1 and NAT2 genotypes and the therapeutic response to aminosalicy‐
lates [68,69].
4.2. Glucocorticoids
Glucocorticoids (GCs) play an important role in the IBD therapy but like other drug groups,
they are now used not in the causal therapy but in the symptomatic therapy. Glucocorti‐
coids (GCs) are broadly used to inhibit common inflammatory and autoimmune reactions of
the body. They play a crucial role in the CD therapy, especially during the high activity of
the disease. GCs are effective for the treatment of active inflammation but not for the main‐
taining of remission and prevention of relapses. Despite the massive boom of other drugs,
they keep their position of golden standard in the IBD therapy.
Corticosteroids have anti-inflammatory and immunomodulating properties – mainly immu‐
nosuppressive. Their anti-inflammatory effect is partly immediate; peaking within 6 hours
of the GCs injection application and subsiding within 24 hours. This is connected with quan‐
titative changes in circulating leucocytes. GCs are at high doses affecting B-lymphocytes.
Furthermore, they can lead to the decreased production of IgA and IgG 2-3 weeks after the
onset of the therapy. Anti-inflammatory effect, which starts later, is a long-term with an im‐
pact on T-lymphocytes, especially Th-lymphocytes, and substantially less on Ts-lympho‐
cytes [70]. However, quite limiting factors in the therapeutic use of GCs are various adverse
effects during a long-term use, which are mainly connected with their numerous physiologi‐
cal functions in the body. The toxicity of corticosteroids is insignificant and physiological
doses are administered during the substitution therapy, adverse effects do not develop.
They only occur after administering of high doses during anti-inflammatory and immuno‐
suppressive therapy.
GCs are highly lipophilic substances, which easily penetrate membranes of target cells and
bind to specific glucocorticoid receptors. GCs complexes + receptor form homodimers,
which are transported into the cell nucleus. Here they bind to specific responsive DNA
structures of various genes. The result of this interaction is a changed gene transcription.
The inhibition of promoters for the AP-1 gene (activator protein 1) or NF-κB (nuclear factor
kappa B), which are transcription factors for pro-inflammatory cytokines, and then induc‐
tion of IκBα (inhibitor kappa B alfa), which is able to bind and therefore inhibit NF-κB, are
important for the immunosuppressive and anti-inflammatory effect of GCs.
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Terminating of the corticoidsteroid therapy leads in a part of patients to the disease relapse.
To maintain the remission state, their long-term administering is therefore necessary; we
talk about the so-called corticodependence. The opposite problem is corticoresistance, i.e.
condition, when administering of GCs does not lead to the calming down of the disease or
remission. Corticoresistance occurs in 16-20% of patients; corticodependence in 28-36% of
treated patients [71,72]. Corticoresistance is not only the problem of Crohn’s disease and has
been intensively studied [73].
4.2.1. Polymorphisms influencing glucocorticoid therapy
Corticoresistance is mainly associated with polymorphisms in the MDR1 gene (multidrug
resistance gene). P-glycoprotein (P-gp) coded by this gene is a membrane protein serving
as  an  ATP-dependent  transporter  of  xenobiotics  from cells.  Polymorphism in  this  gene
was described for the first time in tumour cells in connection with the occurrence of the
multidrug resistance of  anticancer  drugs [74].  However,  the  MDR1  gene is  also  present
in normal tissue with excretion functions,  i.e.  the intestines,  liver,  kidneys,  placenta and
testes.  It  is  also  formed in  brain  capillary  endothelial  cells,  where  it  participates  in  the
function  of  the  blood-brain  barrier  [75].  P-glycoprotein  in  these  tissues  is  probably
formed as  a  defence  mechanism against  xenobiotics.  It  is  an important  regulator  of  the
biological  activity  and  tissue  distribution  of  various  drugs,  and  it  participates  in  their
transport  from cells  into  the  extracellular  environment.  The  increased activity  of  the  P-
glycoprotein  pump is  one  of  the  reasons  for  the  multidrug resistance  of  cancer  cells  to
cytostatic  drugs,  and it  is  assumed that  it  could cause the non-responsiveness to gluco‐
corticoids.
MDR1  gene  is  located  on  the  7q  chromosome  and  consists  of  28  exons.  Farrell  et  al.
proved the increased expression of this gene in T-lymphocytes and in the cells of the in‐
testinal epithelium in patients with UC and CD, who had to undergo an intestine resec‐
tion  after  the  failure  of  drug  therapy  [76].  Therefore,  the  level  of  the  MDR1  gene
expression significantly influences the therapeutic response to the administered glucocor‐
ticoides (GCs).  An indirect  dependence between the cells’  sensitivity to GCs and MDR1
expression was also described [77].
The presence of polymorphisms in the MDR1 gene can influence the gene expression, its
amount and also the function of the P-glycoprotein pump, based on the mutation place and
character. Substitutions of amino acids in the primary protein structure can result in changes
of the substrate spectrum and the effectiveness of transport or pump sensitivity to specific
inhibitors. These two mechanisms can also be combined.
Polymorphism in  the  MDR1  gene  was  described  for  the  first  time  in  1989  [78].  MDR1
variants and their  functional  impact  are still  being studied intensively.  To date,  50 SNP
and 3 deletion and insertion mutations has been described [79,80].  From the perspective
of the biological availability of glucocorticoids, mutations in exon 12 (e.g. 1236C>T), exon
21 (2677G>T/A) and exon 26 (3435C>T) have been studied more predominantly [81].The
most  frequent  polymorphisms  have  a  character  of  substitution  at  position  2677,  where
guanine  usually  occurs,  or  possibly  thymine  and  less  frequently,  alanine  (2677G>T/A).
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Some authors assume that the reason for the increased transport activity of MDR1 is be‐
cause of this polymorphism [83].  In contrast,  mutation 3435C>T in exon 26 is  connected
with a low expression of P-glycoprotein in the small intestine. The frequency of this mu‐
tation in the Caucasian population reaches 28.6% [83].  Carriers  of  the homozygous var‐
iant  genotype  TT  showed  a  lower  production  of  intestinal  P-glycoprotein,  when
compared  with  standard  homozygotes  of  the  CC  genotype.  Several  studies  imply  that
the  frequency  of  the  CC  genotype  is  significantly  higher  in  African  populations,  when
compared with  Caucasian  and Asian  populations  [84,85].  It  could  be  speculated  that  it
might provide the African population with a certain selective advantage against GIT in‐
fections,  which  are  endemic  in  tropical  regions,  because  P-glycoprotein  plays  a  crucial
role in the defence against bacterial and viral infections. The physiological role of P-gly‐
coprotein lies in the protection against entering bacterial toxins into the intestinal muco‐
sa. This hypothesis is supported by Panwala [86], who demonstrated that knockout mice
are sensitive to the development of severe spontaneous intestinal inflammations.The am‐
biguous results of the studies focusing on the impact of individual SNPs on the expres‐
sion or function of the P-glycoprotein pump were brought into consonance by the results
of  haplotype  analysis,  which  found a  correlation  between  mutations  3435C>T,  2677G>T
and 1236C>T. Potocnik [87] demonstrated a significantly higher risk of resistance to glu‐
cocorticoids in carriers of the haplotype marked as T/T/T.
The MDR1 gene is also included in the group of so-called candidate genes for IBD. At
present, the relationship is being studied between the polymorphism 3435C>T, which re‐
sults in the decreased expression of P-glycoprotein and the increased susceptibility to the
development of IBD... Another cause of corticoresistance is examined on the level of the glu‐
cocorticoid receptor (GR). It could be because of the disturbed receptor function or the
change of its expression.
Glucocorticoid receptor (GR) exists in two isoforms (GR-α, and GR-β), which are formed by
an alternate splicing of hnRNA to mRNA. Only the GR-α isoform, whose expression many
times exceeds the expression of GR-β, is able to bind glucocorticoids and mediate their ef‐
fect. Corticoresistant patients showed a higher expression of the GR-β isoform, but when
compared with GR-α, this amount was still very little [88,89]. In-vitro obtained data imply
that the formation of GR-β isoform is inducible and can be influenced by cytokines IL-2 and
IL-4 [90,91] as well as by glucocorticoids [92]. The question is, how GR-β participates in
modulating the sensitivity of an organism to glucocorticoids.
Polymorphisms ER22/23EK, located in exon 2, consist of two point mutations - substitutions
in codons 22 and 23. The first mutation is silent, changing codon 22 from GAG to GAA (both
code glutamic acid). The consequent mutation in codon 23, AGG→AAG, leads to the substi‐
tution of arginine for lysine [93]. ER22/23EK is associated with the decreased sensitivity (rel‐
ative resistance) to glucocorticoids [94]. Its mechanism probably lies in the changed ratio
between the forming translation isoforms GR-α and GR-β, in favour of the weaker transacti‐
vator GR-A α [93]. Two other polymorphisms in the gene GR, 363Asn>Ser in exon 2 and Bcl
I, are associated with hypersensitivity to GCs [95–97]. A study in 119 IBD patients observed
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a more frequent occurrence of the Bcl I polymorphism in individuals responsive to GCs
therapy [97].
Mutation 641Arg>Val and 729Ile>Val, that lead to the expression of receptors with a de‐
creased affinity for exogenously supplemented corticosteroids, including Dexametasone,
were described in the binding domain for the glucocorticoid receptor. The negative feedback
induced by glucocorticoid resistance leads to the increased production of cortisol in the
adrenal gland. This increased adrenal activity also leads to an increased production of an‐
drogens and mineralocorticoids [95,98,99]. In contrast, a polymorphism (363Asn>Ser) in
exon 2 leading to an increased sensitivity to dexamethasone was also observed [100]. Yet an‐
other potential predictor of glucocorticoids’ effectiveness from the group of polymorphisms
of the gene for the corticoid receptor seems to be polymorphism BcI I, in which an associa‐
tion between hypersensitivity and glucocorticoids [97].
Since corticoresistance is most often observed in severely afflicted patients, it is still unclear
whether corticoresistance is a singular phenomenon or whether it is caused by an exhaus‐
tion of the anti-inflammatory capacity of glucocorticoids due to an excessive production of
pro-inflammatory cytokines, which, in turn, is caused by the excessive activity of several in‐
tracellular transcription factors that can also reduce the affinity of the glucocorticoid recep‐
tor for its intracellular ligands [101]. The results of several studies imply that the relative
corticoresistance of T-lymphocytes could possibly be conditioned by their contact with pro-
inflammatory cytokines and the consequential decrease of GR affinity for ligands [91]. How‐
ever, this explanation of corticoresistance is not satisfactory because state of remission can
be achieved in a substantial number of patients with a severe form of the disease by cortico‐
therapy, even though their T-lymphocytes are exposed to the same conditions as the non-
responders.
So far, no clinical or genetic marker exists which could be used to predict whether glucocor‐
ticoid therapy would lead to the desired therapeutic response, or that the inflammation
would be corticoresistant.
4.3. Thiopurines
Thiopurine analogues (azathioprine, 6-mercaptopurine) were therapeutically used as immu‐
nosuppressives in the early 1950s for the first time. They are chemical thiol analogues of en‐
dogenous purine compounds. Azathioprine is one of the most commonly used drug in this
group. The effect of azathioprine, just like its potential toxicity, depends on the amount of its
active metabolites or the administered dose. Azathioprine metabolism is so complex that it
is obvious that the levels of active and inactive metabolites correlate with the activity of met‐
abolic enzymes. Scientific teams focused on the research of variant alleles of the genes for
TPMT, ITPA and XDH, which are key enzymes for the metabolism of thiopurines, in which
it is possible to expect an impact on the phenotype or on the decreased enzymatic activity of
the native protein. Variant alleles can indirectly influence azathioprine’s effect and incidence
of its toxicity manifestations by this mechanism.
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structures. Therefore, the impact on the biological functions of the coded protein is minimal
[188]. The insertion of cytosine nucleotide in the case of the frameshift mutation leads to the
shift of the reading frame during the translation and the formation of a premature stop co‐
don [190]. The transcription of the variant allele results in the production of a protein, which
is shorter by the area coded behind the stop codon. Due to this, the biological activity of the
shortened protein NOD2 is strongly disturbed, which was confirmed by in vitro and in vivo
studies, which discovered that the production of TNFα was not detected after the stimula‐
tion of MDP [187–189]. The presence of the frameshift mutation therefore results in the ab‐
sence of the TNFα expression via NF-κB [15].
If we accept the hypothesis that a higher effectiveness of infliximab therapy correlates with
lower levels of TNFα, then carriers of the alleles, which are connected with the lower expres‐
sion of this cytokine, should also respond favorably to the therapy. Our results confirm this
hypothesis, even though we did not study the phenotype (plasma or tissue levels of TNFα)
but only the genotype. The frequency of variant alleles, in which the significant influence on
the quantity of the TNFα expression (702W and 908R) was not confirmed in vitro, was com‐
parable in patients with a therapeutic response and in patients resistant to the therapy. On
the other hand, the frequency of the frameshift mutation, which leads to a significant de‐
crease of the TNFα expression after the MDP induction, was statistically and significantly
higher (15.2%) in patients who reacted positively to the therapy, compared to patients that
were resistant to the therapy (3.6%). Patients, who are carriers of the frameshift mutation,
have a 4.25 times higher probability that the infliximab therapy will be effective (CI 95%;
1.06-17.07). The frequency of the frameshift mutation (variant allele 1007fs) was virtually
identical in patients who responded to the infliximab therapy by mucosal healing, and in
patients who revealed only clinical improvement of parameters (15.15% and 15.22%, respec‐
tively).
The TNFα expression via NF-κB occurs also after the binding of a specific ligand, e.g. lipo‐
polysaccharide (LPS), to the membrane TLR4 receptor. The activation of the intracellular sig‐
nalling cascade and the expression of pro-inflammatory cytokines occur in cooperation with
the molecule CD14 [191]. In the TLR4 gene, there are nucleotide polymorphisms, which in‐
fluence its biological functions [192,193]. One of these is a substitution of adenine by gua‐
nine at the position 896 of the nucleotide chain. The variant allele 896G has a lower ability to
induce TNFα production in reaction to LPS stimulation in the in vitro experiments [192,193].
Analogically to the variant genotype NOD2, there is a possible hypothesis that the variant
allele 896G is associated with a better therapeutic response. The occurrence of variant allele
in our set was the highest in patients who responded best to infliximab therapy, i.e. those
who showed both a clinical and morphological response to the therapy (9.9%). In patients
with only a clinical response, the frequency of the variant allele was lower (3.6%), and
among patients resistant to the therapy, there were only 1.8% of carriers of the variant allele.
We can describe a certain tendency that a carrier of the variant allele has a greater probabili‐
ty that infliximab therapy will be effective. However, differences in the frequencies of the
variant allele 896G in the TLR4 gene between individual groups of patients were not statisti‐
cally significant. According to the odds ratio, there are 2.59 patients with both a clinical and
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morphological reaction per one patient, with a clinical reaction in the group of patients with
a variant allele 896G in the gene TLR4 (CI 95%; 1.01-8.39) [175].
Several polymorphisms influencing the expression degree were described in the promoter
area of the gene coding for TNFα. A single nucleotide substitution –308G>A is often men‐
tioned. Production of TNFα can be increased by this mechanism even under the standard
stimulation conditions. The variant allele –308A occurred with a 14.03% frequency in the set
of patients. Even though according to the in vitro testing, this variant allele means a higher
production of TNFα due to a higher transcription activity of the gene [194], it could be ex‐
pected that it will be more frequent in patients resistant to the therapy. Our results did not
confirm statistically significant differences between individual groups of patients.
Based on the above information, it can be concluded that a patient who is a carrier of a geno‐
type containing variant allele 1007fs in the gene NOD2, variant allele 896A in the gene TLR4
and the standard allele –308A in the gene TNFα, they will have the greatest probability that
the infliximab therapy will be effective for them. Individuals who are homozygous for the
standard (wild type) alleles of the listed polymorphisms in the gene NOD2, TLR4 and TNFα,
are more often resistant to the infliximab therapy. This standard genotype was in our study
of 163 infliximab-administered patients confirmed in up to 75% of resistant patients, com‐
pared with 46.7% in the group with a therapeutic response. In patients with the best re‐
sponse to infliximab, (i.e. both clinical and morphological) the frequency of this allele
combination was even lower (43.9%) – see Figure 4.
Figure 4. Occurrence (in %) of genotype consisted from wild type alleles in polymorphisms NOD2:1007fs, TLR4:
896A>G and TNFα: –308G>A in groups of patients with different response to infliximab therapy. Legend: C - M re‐
sponse - patients with clinical and morphological response to infliximab therapy; C response - patients with clinical
response, but without morphological response; Therapeutic response - total number of patients in both groups (CM +
C); Resistant patients = patients without clinical and without morphological response to infliximab therapy
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Patients who are carriers of the standard genotype, are 2.13 times more probable to be resist‐
ant to the infliximab therapy (CI 95%; 1.10-4.13) compared with patients with other allele
combinations [175].
In the group of patients with the genotype containing standard alleles of the monitored
polymorphisms, there were 3.43% of individuals resistant to the therapy per one individual
with a therapeutic response (CI 95%; 1.37-8.60). Patients, in whom the infliximab administer‐
ing resulted in a therapeutic response, were also most often carriers of the combination
1007fs mut in NOD2 gene, wt allele in TLR4 gene and wt allele in TNFα gene (17%). The
genotype containing standard alleles (wt) of NOD2 and TLR4 genes, i.e. the genotype corre‐
sponding to the standard expression activity of TNFα, was significantly more often present‐
ed in individuals resistant to the therapy (89.3%). The genotype composed of at least one
variant allele responsible for the lower expression activity of TNFα was significantly more
common in patients with a therapeutic response (32.6%; P=0.02).
In the group of patients with the greatest therapeutic benefits (clinical and morphological
response), they most often represented carriers of at least one of the monitored variant al‐
leles (39.4%) [175].
7. Conclusion of chapter – The potential of genotyping of IBD patients in
clinical practice: The importance of gene polymorphisms for
individualisation of IBD pharmacotherapy
Pharmacogenetics is a relatively young branch of pharmacology, which deals with the re‐
search of genetic backgrounds of individual differences in the patient’s response to thera‐
peutic drugs, both from the perspective of drug effectiveness and its safety. Its origin and
development is closely connected with new knowledge in the area of the human genome
and the development of molecular biology methods, which are used in this branch. The first,
partly euphoric visions regarding the use of pharmacogenomic findings for pharmacothera‐
py individualisation and personalised medicine were later revised thanks to the empirical
experience from applying theoretical hypotheses into medical practice. The difference be‐
tween theoretical hypothesis and empirical findings results from the complicated biological
system both at the level of genome and its regulatory mechanisms, and at the level of pro‐
teosynthesis, signalling pathways and interactions of intracellular molecules. The more we
know about the human genome, the more we realise that we can only guess how many of its
regions are activated in a decisive moment, and how complex the regulatory mechanisms
are which influence the final effect, and resulted in phenotype.
The clinical application of pharmacogenetic findings can be limited by the existence of non-
genetic factors. Even though genome cannot be influenced by external factors, the drug to
drug interaction which occurs in the organism can influence not only the onset and develop‐
ment of a disease, but also the patient’s response to the drug. Furthermore, it is necessary to
remember that the patient’s sensitivity to external factors is also a variable and that it is also
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genetically conditioned. Because of this, pharmacogenetic information alone cannot predict
exactly the effectiveness or safety of a drug. Despite this, pharmacogenetic studies have pro‐
vided much significant information regarding the different rate of drug metabolisation in in‐
dividuals as well as in populations, the effectiveness of various therapies and the
development of serious adverse effects. Pharmacogenetics is a promising tool in the indi‐
vidualisation of the doctor-patient approach.
The characteristic presence of some polymorphisms in the “candidate genes” is connected
with a predisposition to IBD. It seems that Crohn’s disease is more genetically conditioned
than ulcerative colitis. Some polymorphisms are typical for CD, others for UC. In patients
with CD, the frameshift mutation is statistically more often present in the gene NOD2/
CARD15 (Leu1007fs insC) and the substitution mutation 469Lys>Glu in the gene ICAM-1
than in a healthy population. Unlike patients with UC, they less often carry the substitution
mutation 702Arg>Trp in the gene NOD2/CARD15. All three studied mutations in the gene
NOD2/CARD15 (Leu1007fs insC, 702Arg>Trp and 908Gly>Arg) are statistically more fre‐
quent in patients diagnosed with CD than in patients with UC. Genetic analysis could there‐
fore help find individuals with a genetic predisposition that would require more frequent
check-ups, or to inform physicians when to use additional endoscopic and laboratory tests
or to help specify ambiguous diagnosis.
IBD therapy is lengthy; therefore it requires an individual choice of a drug with an aim to
reduce or completely eliminate adverse effects, while at the same time maintain the therapy
effectiveness. The aim is to achieve a maximum pharmacotherapeutic effect as well as the
effective use of finance. The presence of variant alleles of polymorphisms in “therapeutic
genes” can be of significant help in predicting the adverse effects of a given therapy. The
relationship between myelosupression and the presence of variant alleles in the gene for
TPMT is of the greatest interest. The frequency of variant alleles is significantly higher in pa‐
tients who experience leukopenia during azathioprine therapy, than in patients in whom
leukopenia does not develop. TPMT genotyping can therefore serve as a marker which will
notify clinicians of a significantly increased potential risk in patients with a certain geno‐
type, and on the necessity of increased surveillance over the patient or the need to adjust the
dosage. In clinical practice, it is now common to determine variant alleles in the TPMT gene
prior to the azathioprine therapy. This allows individualisation of the therapy and prevents
serious complications.
Another desired goal is to find genetic markers which can potentially influence the effective‐
ness of pharmacotherapy, especially a therapy which is costly, such biological therapy for
example. Our experimental data imply that patients who are carriers of a genotype com‐
posed from the variant allele 1007fs in the gene NOD2, variant allele 896A in the gene TLR4
and standard allele –308A in the gene for TNFα will have the highest probability that inflixi‐
mab therapy will be effective. On the other hand, individuals who are homozygous for
standard (wild type) alleles of the given polymorphisms in the gene NOD2, TLR4 and TNFα,
are more often resistant to infliximab therapy. This standard genotype was confirmed in up
to 75% of patients resistant to the therapy. Patients who are carriers of the standard geno‐
type are 2.13 times more probable to be resistant to infliximab therapy (CI 95%; 1.10-4.13)
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than patients with different allelic combinations. A more complex genotyping of a larger set
of patients could help define the “risk genotype”, whose carriers have statistically and sig‐
nificantly decreased the probability of a full morphological response to anti-TNF therapy, or
in contrast, to define a “positive genotype”, where the probability of a successful therapy
would be very high.
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